Cellebrite/$CLBT
1D1W1MYTD1Y5YMAX
Capital at risk
About Cellebrite
Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.
- Ticker
- $CLBT
- Sector
- Software & Cloud Services
- Primary listing
- NASDAQ
- Employees
- 1,285
- Headquarters
- Petah Tikva, Israel
- Website
- www.cellebrite.com
Cellebrite Metrics
BasicAdvanced
$2.8B
49.32
$0.23
1.18
-
Price and volume
Market cap
$2.8B
Beta
1.18
52-week high
$19.98
52-week low
$9.58
Average daily volume
3.9M
Financial strength
Current ratio
1.619
Quick ratio
1.519
Long term debt to equity
3.251
Total debt to equity
4.317
Profitability
EBITDA (TTM)
78.427
Gross margin (TTM)
82.96%
Net profit margin (TTM)
11.43%
Operating margin (TTM)
10.86%
Effective tax rate (TTM)
22.05%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
3.92%
Return on equity (TTM)
12.42%
Valuation
Price to earnings (TTM)
49.322
Price to revenue (TTM)
5.411
Price to book
5.28
Price to tangible book (TTM)
9.57
Price to free cash flow (TTM)
21.649
Free cash flow yield (TTM)
4.62%
Free cash flow per share (TTM)
0.523
Growth
Revenue change (TTM)
17.76%
Earnings per share change (TTM)
-134.98%
3-year revenue growth (CAGR)
20.54%
3-year earnings per share growth (CAGR)
-0.42%
What the Analysts think about Cellebrite
Analyst ratings (Buy, Hold, Sell) for Cellebrite stock.
Analyst projections of the future price of Cellebrite stock.
Bulls say / Bears say
Cellebrite continues to deliver strong recurring growth: Q2 ARR reached $507.8 million, up 21% year over year, while dollar-based net retention improved to 117%, indicating healthy expansion within its customer base. (SEC filing)
The product pipeline is gaining commercial traction: Genesis achieved early monetization in Q2, and the company reported adoption of Guardian Investigate, drone-forensics capabilities, and Advanced Unlocks. (SEC filing)
Cellebrite’s cash-generation and cost discipline remain favorable: trailing-twelve-month free cash flow was $144.2 million, while management raised FY2026 adjusted EBITDA guidance to $153–$159 million despite reducing revenue and ARR expectations. (SEC filing)
Cellebrite lowered its FY2026 outlook after Q2 ARR came in below expectations, citing longer sales cycles and weaker-than-expected expansion from Inseyets conversions; full-year ARR guidance fell to $550–$560 million and revenue guidance to $555–$561 million. (SEC filing)
Execution and leadership risk have increased: the company changed CEOs in August 2026, while management acknowledged that newer products may contribute more slowly because of elongated sales cycles and product-launch timing. (SEC filing)
Profitability quality weakened year over year in Q2: GAAP gross margin declined to 80.8% from 84.4%, operating margin fell to 5.3% from 12.7%, and net income dropped to $6.4 million from $19.5 million. (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Cellebrite Financial Performance
Revenues and expenses
Cellebrite Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cellebrite News
AllArticlesVideos
Kaplan Fox Encourages Cellebrite DI Ltd. (CLBT) Investors Who Suffered Losses to Contact the Firm About the Securities Investigation
Newsfile Corp20 hours ago
Kaplan Fox Urges Cellebrite DI Ltd. (CLBT) Investors to Contact the Firm About Possible Securities Law Violations
Newsfile Corp3 days ago
Kaplan Fox Encourages Investors of Cellebrite DI Ltd. (CLBT) to Contact the Firm to Learn About Their Legal Rights
Newsfile Corp1 week ago
Funds containing Cellebrite
AllUSDEURGBP
Fund name | Fund size | $CLBT weighting |
|---|---|---|
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.02% |
Amundi Prime All Country World€WEBN | €3.2B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.